Calgary Depression Scale for Schizophrenia (CDSS)

Abstract

The Calgary Depression Scale for Schizophrenia (CDSS) is a specialized, nine-item structured interview scale developed in 1990 by Donald Addington and his colleagues. Its primary function is to accurately assess symptoms of depression in individuals diagnosed with schizophrenia, critically ensuring that the measurement is independent of the confounding positive and negative symptoms associated with psychosis. The CDSS was designed specifically to address the known limitations of traditional depression scales (such as the Beck Depression Inventory or the Hamilton Depression Rating Scale) when applied to psychotic populations, where symptom overlap often leads to misdiagnosis or inflated depression scores.

Keywords

Calgary Depression Scale, CDSS, Schizophrenia, Depression, Affective Symptoms, Psychometrics, Rating Scale, Major Depressive Episode, Psychosis.

Authors

Donald Addington, Jean Addington, E. Maticka-Tyndale, B. Schissel, J. Joyce.

Purpose

The core purpose of the CDSS is to provide a reliable, valid, and highly specific instrument for measuring depressive symptomatology exclusively in patients suffering from schizophrenia. This development was crucial because depression is highly prevalent in this population (reported in 7–75% of patients, averaging 25%), and its presence significantly impacts diagnosis, treatment efficacy, and long-term prognosis, including increased risk of suicide.

The scale was explicitly engineered to differentiate true depressive symptoms from the overlapping features of schizophrenia, particularly negative symptoms (e.g., affective flattening, apathy) or medication-induced side effects (e.g., extrapyramidal symptoms). By isolating the depressive construct, the CDSS serves as a vital clinical tool for monitoring and guiding the treatment of comorbid depression in psychotic disorders.

Construct

The CDSS measures the psychological construct of depressive pathology specifically adapted for individuals experiencing schizophrenia. It focuses on symptoms that are least likely to be confounded by primary psychosis symptoms. Initially an 11-item scale, it was refined to the current nine-item structure through comprehensive validation against established scales like the Hamilton Depression Rating Scale (HDRS) and the Beck Depression Inventory (BDI).

The nine items assess core depressive features, ranging from subjective emotional states to observable behaviors and biological markers. These include key indicators of mood disturbance, negative self-perception, and biological symptoms often indicative of a Major Depressive Episode (MDE).

Validity

The CDSS demonstrates high levels of validity, confirming its utility as the most specific measure of depression in patients with schizophrenia. Validity was established through multiple methods, including correlation with other depression measures and confirmatory factor analysis.

• Construct Validity: Strong evidence supports that the CDSS measures a single, unified dimension of depression. This was confirmed by correlations with other depression rating scales and its robust ability to predict the presence of an MDE.
• Divergent Validity: Crucially, the CDSS exhibited an absence of substantial correlations with positive symptoms, negative symptoms, and extrapyramidal symptoms. This divergent validity is the defining feature that allows it to successfully isolate depressive symptoms from the core pathology of schizophrenia.
• Criterion Validity: The scale possesses high sensitivity (85%) and specificity (82%) for predicting the presence of a Major Depressive Episode when the summed total score exceeds 6 points. All individual items significantly discriminate between the presence and absence of an MDE.

Reliability

Psychometric evaluation confirms that the CDSS maintains strong internal consistency and reliability, making it a dependable instrument for clinical use.

• Internal Consistency: The scale consistently demonstrates high internal consistency, reported with a Cronbach’s alpha ($alpha$) ranging from 0.76 to 0.86 across various studies.
• Inter-Rater Reliability: The structured interview format contributes to good internal and inter-rater reliability, ensuring consistency across different experienced clinicians administering the scale.
• Sensitivity to Change: The CDSS is highly sensitive to changes in depressive symptoms over time, allowing clinicians to utilize the scale effectively during both the acute and residual stages of schizophrenia to monitor treatment response.

Factor Analysis

The development and refinement of the CDSS utilized factor analysis to confirm that the nine selected items loaded onto a single factor representing depression, distinct from other symptom domains relevant to schizophrenia. This statistical validation was pivotal in ensuring the scale’s specificity.

The confirmatory factor analysis demonstrated that the CDSS items maintain low correlation with positive and negative symptoms and show no substantial correlation with extrapyramidal symptoms. This psychometric achievement reinforces the CDSS’s superior capability compared to general depression scales, such as the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Scale, in differentiating affective symptoms from primary psychotic pathology.

Instrument

Test Type: Structured Interview Rating Scale (Clinician-administered)

Format: Nine-item scale utilizing a 4-point Likert type scale (0 = absent; 1 = mild; 2 = moderate; 3 = severe), with detailed descriptors anchoring each point. Point scores are summed, yielding a total depression score. A score higher than 6 is highly predictive of a Major Depressive Episode.

Language Available: Extensive translation, validated in over 40 languages, including Arabic, Spanish, German, Chinese, Thai, Brazilian, Greek, and French.

Population Group: Clinical populations diagnosed with schizophrenia and related disorders (DSM-III-R, DSM-IV criteria). Also validated for use in youth at clinical high risk for psychosis.

Age Group: Primarily adults, but applicability extended to youth in research settings.

Population Details: Focused on maximizing internal and external validity across both inpatient and outpatient settings. Requires administration by an experienced rater; it is not designed for self-assessment.

Test Methodology: The assessment involves eight structured questions and a ninth observational item that relies on the rater’s clinical observation throughout the course of the interview.

Keywords

CDSS, Schizophrenia Depression, Comorbidity, Psychometrics, Structured Interview, BDI, HDRS, Extrapyramidal Symptoms, Clinical Assessment, Diagnostic Specificity.

Authors

Author ORCID Identifier: Information not provided in source content.

Affiliation Email addresses: Information not provided in source content.

Correspondence Address: Information not provided in source content.

Permissions & Fee and Test Year

The scale was initially developed and published in 1990 (Donald Addington et al., 1990). Information regarding current commercial licensing fees or specific permission requirements for widespread clinical or commercial use is not detailed in the source material, though the scale is broadly utilized in academic and clinical research globally.

Reference’s

• Addington, D., Addington, J., & Maticka-Tyndale, E. (1991). Reliability and validity of a depression scale for schizophrenics. Schizophrenia Research, 4(3), 247. https://doi.org/10.1016/0920-9964(91)90089-A
• Addington, D., Addington, J., & Maticka-Tyndale, E. (1994). Specificity of the Calgary Depression Scale for schizophrenics. Schizophrenia Research, 11(3), 239-244. https://doi.org/10.1016/0920-9964(94)90017-5
• Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6(3), 201-208. https://doi.org/10.1016/0920-9964(92)90003-N
• Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3(4), 247-251. https://doi.org/10.1016/0920-9964(90)90005-R
• Addington, J., Shah, H., Liu, L., & Addington, D. (2014). Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. Schizophrenia Research, 153(1), 64-67. https://doi.org/10.1016/j.schres.2013.12.014
• Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., Tran, N. (2016). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry, 50(5), 410-472. doi:10.1177/0004867416641195
• Kim, S.-W., Kim, S.-J., Yoon, B.-H., Kim, J.-M., Shin, I.-S., Hwang, M. Y., & Yoon, J.-S. (2006). Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Research, 144(1), 57-63. https://doi.org/10.1016/j.psychres.2005.10.002
• Lançon, C., Auquier, P., Reine, G., Bernard, D., & Toumi, M. (2000). Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS). Journal of Affective Disorders, 58(2), 107-115. https://doi.org/10.1016/S0165-0327(99)00075-0
• Müller, M. J., Brening, H., Gensch, C., Klinga, J., Kienzle, B., & Müller, K.-M. (2005). The Calgary Depression Rating Scale for schizophrenia in a healthy control group: Psychometric properties and reference values. Journal of Affective Disorders, 88(1), 69-74. https://doi.org/10.1016/j.jad.2005.04.005

Items of the Calgary Depression Scale for Schizophrenia (CDSS)

IMPORTANT: The following scale items must be preserved in their original language and must not be changed in any way.

1. Depression
2. Hopelessness
3. Self deprecation
4. Guilty ideas
5. Pathological guilt
6. Morning depression
7. Early wakening
8. Suicidal ideation
9. Observed depression